1976
Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Ihde D, DeVita V, Canellos G, Young R. Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. Blood 1976, 47: 211-22. PMID: 1244920, DOI: 10.1182/blood.v47.2.211.bloodjournal472211.Peer-Reviewed Original ResearchConceptsTolerance to combination chemotherapyCombination chemotherapyHodgkin's diseasePlatelet countControl patientsBone marrow lymphomaSplenectomy per seCycles of therapyNon-Hodgkin's lymphomaCycles of treatmentMatched control patientsPortion of patientsEffect of splenectomyLymphoma patientsInitial treatmentStaging procedureLymphomaTotal doseSplenectomyChemotherapyLeukocyte countPatientsHodgkinLeukocytesPlateletEffect of Splenectomy on Tolerance to Combination Chemotherapy in Patients With Lymphoma
Ihde D, DeVita V, Canellos G, Young R. Effect of Splenectomy on Tolerance to Combination Chemotherapy in Patients With Lymphoma. Blood 1976, 47: 211-222. DOI: 10.1182/blood.v47.2.211.211.Peer-Reviewed Original ResearchTolerance to combination chemotherapyCombination chemotherapyHodgkin's diseasePlatelet countControl patientsBone marrow lymphomaSplenectomy per seCycles of therapyCycles of treatmentMatched control patientsPortion of patientsEffect of splenectomyHodgkin lymphomaLymphoma patientsInitial treatmentStaging procedureLymphomaTotal doseSplenectomyChemotherapyLeukocyte countHodgkinPatientsLeukocytesPlatelet
1975
Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
Canellos G, Young R, Neiman P, DeVita V. Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood 1975, 45: 197-203. PMID: 1054609, DOI: 10.1182/blood.v45.2.197.bloodjournal452197.Peer-Reviewed Original ResearchConceptsTreatment of chronic granulocytic leukemiaBusulfan-treated patientsChronic granulocytic leukemiaGranulocytic leukemiaMedian duration of disease controlChronic phase of CGLDuration of disease controlContinuous maintenance therapyElevated leukocyte countTreated with busulfanIncreased skin pigmentationMyelosuppressive actionRemission inductionMaintenance therapyMedian survivalMedian durationBlastic transformationPulmonary fibrosisBusulfanRandomized comparisonChronic phaseLeukocyte countDibromomannitolPatientsCytological dysplasiaDibromomannitol in the Treatment of Chronic Granulocytic Leukemia: A Prospective Randomized Comparison With Busulfan
Canellos G, Young R, Nieman P, DeVita V. Dibromomannitol in the Treatment of Chronic Granulocytic Leukemia: A Prospective Randomized Comparison With Busulfan. Blood 1975, 45: 197-203. DOI: 10.1182/blood.v45.2.197.197.Peer-Reviewed Original ResearchTreatment of chronic granulocytic leukemiaBusulfan-treated patientsChronic granulocytic leukemiaGranulocytic leukemiaRandomized comparisonMedian duration of disease controlChronic phase of CGLDuration of disease controlContinuous maintenance therapyElevated leukocyte countTreated with busulfanProspective randomized comparisonIncreased skin pigmentationMyelosuppressive actionRemission inductionMedian survivalMaintenance therapyMedian durationBlastic transformationPulmonary fibrosisBusulfanChronic phaseLeukocyte countDibromomannitolPatients